Everything below concerns Reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
=== John-Daniel Stern === John-Daniel "JD" Stern (Adain Bradley) is Harper's estranged twin brother, who disappeared from her life when the two were teenagers. In series 2, Harper tracks down her brother to Berlin, where he works as a line cook. The two spend the night at a club, and the next morning, JD relapses on his meth addiction. The two have a vicious argument over their childhood growing up with an abusive mother; JD reveals he ran away in part due to Harper exacerbating the pressure their mother put on him to be a star tennis player, but Harper maintains that she too escaped a traumatic upbringing. Harper begs JD to come home with her, but rebuffs her, branding his sister a selfish narcissist who was complicit in the abuse he suffered. Harper is left deeply shaken by the encounter. In series 4, JD calls Harper to tell her that their mother died in a freak accident, having fallen down the stairs while collecting an Amazon delivery. Harper struggles to grieve her mother's death given her traumatic childhood, as well as her preoccupation with her work.
Following a controversial constitutional amendment on 31 July 2025, the Legislative Assembly enabled indefinite reelection, extended presidential terms from five to six years, and eliminated the two-round system.
In Half-Life: Blue Shift, Rosenberg makes his first appearance during the Hazard Course tutorial, long before Calhoun encounters him in the train yards. He can be seen behind the observer's window during the duck-jump portion of the training. Sometime between Gina and Colette's last sight of Rosenberg in Decay and Calhoun's eventual rescue of the scientist in Blue Shift, he tries to enact an escape plan to get out of Black Mesa with the help of several other scientists. During this time, he is captured by soldiers and held captive in a freight car for questioning, while a colleague, Harold, is cornered and fatally wounded. Before Harold dies, Barney Calhoun discovers him, and he instructs Calhoun to find Dr. Rosenberg to help him with his plan. Calhoun is able to reach the train yards and free Dr. Rosenberg. Rosenberg informs him that their plan is to use the equipment in the prototype labs to teleport to safety. He leads Calhoun to the unused part of the complex where two other scientists, Walter Bennett and Simmons, are already preparing the machine. Rosenberg instructs Calhoun that he must activate and align a relay device on Xen in order for them to be able to accurately set their destination. Calhoun travels to Xen and is successful in accomplishing this task, but after returning through the portal back to Earth (it is here that Gina and Colette in Decay, temporarily caught in a harmonic reflux, hear Rosenberg's voice calling Calhoun through the portal), they discover that they need another power cell to replenish the teleporter's power for their escape.
Sources: en.wikipedia.org
== History == Vacutainer technology was developed in 1947 by Joseph Kleiner, and is currently marketed by Becton Dickinson (B-D). The Vacutainer was preceded by other vacuum-based phlebotomy technology such as the Keidel vacuum. The plastic tube version, known as Vacutainer PLUS, was developed at B-D in the early 1990s by E. Vogler, D. Montgomery and G. Harper amongst others of the Surface Science Group as US patents 5344611, 5326535, 5320812, 5257633 and 5246666. Vacutainers are widely used in phlebotomy in developed countries due to safety and ease of use. Vacutainers have the advantage of being prepared with additives, allowing easy multi-tube draws, and having a lower chance of hemolysis. In developing countries, it is still common to draw blood using a syringe or syringes. Many brands have now started manufacturing Vaccutainer such as Vacu-8, Hemo Tube and Hemo Vac Plus. These tubes are now also available in pre-barcoded forms.
Enzymes with this activity include flavanone 7-O-beta-glucosyltransferase, which uses UDP-glucose to transfer the sugar component. Flavanones like naringenin can undergo a rearrangement reaction which converts them first to the unstable hydroxlated isoflavanone, which loses water to give an isoflavone. The enzymes involved are isoflavonoid synthase and 2-hydroxyisoflavanone dehydratase.
=== Interferon === Interferons are produced by the immune system. They are usually involved in anti-viral response, but also have use for cancer. They fall in three groups: type I (IFNα and IFNβ), type II (IFNγ) and type III (IFNλ). IFNα has been approved for use in hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and melanoma. Type I and II IFNs have been researched extensively and although both types promote anti-tumor immune system effects, only type I IFNs have been shown to be clinically effective. IFNλ shows promise for its anti-tumor effects in animal models. Unlike type I IFNs, Interferon gamma is not approved yet for the treatment of any cancer. However, improved survival was observed when Interferon gamma was administered to patients with bladder carcinoma and melanoma cancers. The most promising result was achieved in patients with stage 2 and 3 of ovarian carcinoma. The in vitro study of IFN-gamma in cancer cells is more extensive and results indicate anti-proliferative activity of IFN-gamma leading to the growth inhibition or cell death, generally induced by apoptosis but sometimes by autophagy.
== Living space == Much of the Culture's population lives on orbitals, vast artificial worlds that can accommodate billions of people. Others travel the galaxy in huge space ships such as General Systems Vehicles (GSVs) that can accommodate hundreds of millions of people. Almost no Culture citizens are described as living on planets, except when visiting other civilisations. The reason for this is partly because the Culture believes in containing its own expansion to self-constructed habitats, instead of colonising or conquering new planets. With the resources of the universe allowing permanent expansion (at least assuming non-exponential growth), this frees them from having to compete for living space. The Culture, and other civilisations in Banks' universe, are described as living in these various, often constructed habitats:
Sources: en.wikipedia.org
=== Nominal mass === The nominal mass for an element is the mass number of its most abundant naturally occurring stable isotope, and for an ion or molecule, the nominal mass is the sum of the nominal masses of the constituent atoms. Isotope abundances are tabulated by IUPAC: for example carbon has two stable isotopes 12C at 98.9% natural abundance and 13C at 1.1% natural abundance, thus the nominal mass of carbon is 12. The nominal mass is not always the lowest mass number, for example iron has isotopes 54Fe, 56Fe, 57Fe, and 58Fe with abundances 6%, 92%, 2%, and 0.3%, respectively, and a nominal mass of 56 Da. For a molecule, the nominal mass is obtained by summing the nominal masses of the constituent elements, for example water has two hydrogen atoms with nominal mass 1 Da and one oxygen atom with nominal mass 16 Da, therefore the nominal mass of H2O is 18 Da. In mass spectrometry, the difference between the nominal mass and the monoisotopic mass is the mass defect (see § mass defect. This differs from the definition of mass defect used in physics which is the difference between the mass of a composite particle and the sum of the masses of its constituent parts.
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.
=== JINR–LLNL collaboration === The now-confirmed discovery of element 114 was made in June 1999 when the JINR team repeated the first 244Pu + 48Ca reaction from 1998; following this, the JINR team used the same hot fusion technique to synthesize elements 116 and 118 in 2000 and 2002 respectively via the 248Cm + 48Ca and 249Cf + 48Ca reactions. They then turned their attention to the missing odd-numbered elements, as the odd protons and possibly neutrons would hinder decay by spontaneous fission and result in longer decay chains. The first report of element 113 was in August 2003, when it was identified as an alpha decay product of element 115. Element 115 had been produced by bombarding a target of americium-243 with calcium-48 projectiles. The JINR–LLNL collaboration published its results in February 2004:
Maui Mallard in Cold Shadow – originally released as Donald in Maui Mallard (Japanese: Donald Duck no Maui Mallard (ドナルドダックのマウイマラード)) – is a platforming video game developed and published by Disney Interactive. The game was released in Europe in November 1995, and in Brazil in spring 1997 for the Sega Mega Drive. It was also ported by Eurocom Entertainment Software to the SNES and released in North America in January 1997, in Europe mostly in autumn 1996 (although the SNES version was released in Germany at the end of 1995), and in Japan on December 20, 1996. A Microsoft Windows port was released in North America in November 1996. It was ported one last time to the Game Boy by Bonsai Entertainment Corp., released in North America in August 1998. The game stars Donald Duck in a metafictional role as duck detective Maui Mallard (a spoof of 1980s Hawaii-based TV detective, Magnum P.I. in name and appearance), who adopts the name "Cold Shadow" when he dresses up in ninja garb. In the North American versions of the game, all Donald Duck references are absent, and the protagonist is instead referred to as "Maui Mallard," as, according to composer Patrick Collins, the marketing team felt Donald Duck wasn't cool in the United States. Although the end of the game informed the player to look forward to Maui's next adventure, the planned sequel was cancelled. The game was rereleased on the Steam and GOG digital storefronts on May 17, 2019.
==== Distribution ==== Sumatriptan is a relatively hydrophilic molecule, which may limit its ability to cross the blood–brain barrier and enter the central nervous system. In accordance, early animal studies found lack of indication of central penetration by sumatriptan. This was in contrast to more lipophilic triptans like zolmitriptan, naratriptan, rizatriptan, and eletriptan. For these reasons, it was thought for many years that sumatriptan could not cross the blood–brain barrier in significant amounts to exert central effects. However, in subsequent animal studies, sumatriptan was found to enter the brain and produce centrally mediated effects. Besides animal research, clinical studies have found sumatriptan to produce centrally mediated side effects such as sleepiness, tiredness, thinking difficulty, and dizziness, among others. In addition, sumatriptan has been found to be discernibly psychoactive in human drug discrimination tests, with effects like apathy, sedation, and mild dysphoria. Certain other clinical findings also support centrally mediated effects of sumatriptan. A 2010 literature review concluded that sumatriptan can enter the brain to some minor extent in both animals and humans but that this minor penetration is nonetheless sufficient to cause pharmacological effects. Subsequent research has found sumatriptan given during migraine attacks decreases brain serotonin 5-HT1B receptor binding in humans, with a corresponding receptor occupancy of 16%.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.